| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
o
lu, MD*
, MD*
Department of *Anesthesiology and
Biostatistics, Trakya University, Medical Faculty, Edirne, Turkey
Address correspondence and reprint requests to Doç. Dilek Memi, MD, Trakya Üniversitesi Tp Fakültesi, Anesteziyoloji ve Reanimasyon AD, 22030, Edirne, Turkey. Address e-mail to dilmemis{at}mynet.com
We designed this study to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia (PCA) tramadol use or enhance analgesia. Sixty patients were randomized to receive either oral placebo or rofecoxib 50 mg 1 h before surgery. All patients received a standard anesthetic protocol. Intraoperative blood loss was determined. At the end of surgery, all patients received tramadol IV via a PCA-device. Pain scores, sedation scores, mean arterial blood pressure, heart rate, and peripheral oxygen saturation were assessed at 1, 2, 4, 6, 8, 12, and 24 h after surgery. Total and incremental tramadol consumption at the same times was recorded from the PCA-device. Antiemetic requirements and adverse effects were noted during the first postoperative 24 h. Duration of hospital stay was also recorded. The pain scores were significantly lower in the rofecoxib group compared with the placebo group at 6 times during the first 12 postoperative h (P < 0.05). The total consumption of tramadol (627 ± 69 mg versus 535 ± 45 mg; P < 0.05) and the incremental doses at 1, 2, 4, 6, 8, and 12 h after surgery were significantly more in the placebo group than in the rofecoxib group. There were no differences between groups in intraoperative blood loss, sedation scores, hemodynamic variables, peripheral oxygen saturation, antiemetic requirements, or adverse effects after surgery. The length of hospital stay was also similar in the groups. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy.
IMPLICATIONS: This study was designed to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia tramadol use or enhance analgesia. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy.
This article has been cited by other articles:
|
|
 |
|
  G. Riest, J. Peters, M. Weiss, S. Dreyer, P. D. Klassen, B. Stegen, A. Bello, and M. Eikermann Preventive effects of perioperative parecoxib on post-discectomy pain Br. J. Anaesth., February 1, 2008; 100(2): 256 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. CARDARELLI Recurring Limitations in OMT Research J Am Osteopath Assoc, March 1, 2006; 106(3): 112 - 113. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-F Gramke, J. J. J. Petry, M. E. Durieux, J.-P Mustaki, M. Vercauteren, G. Verheecke, and M. A. E. Marcus Sublingual piroxicam for postoperative analgesia: preoperative versus postoperative administration: a randomized, double-blind study. Anesth. Analg., March 1, 2006; 102(3): 755 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Turan, P. F. White, B. Karamanlioglu, D. Memis, M. Tasdogan, Z. Pamukcu, and E. Yavuz Gabapentin: An Alternative to the Cyclooxygenase-2 Inhibitors for Perioperative Pain Management Anesth. Analg., January 1, 2006; 102(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huang Efficacy of the NSAIDs Depends on Multiple Factors Anesth. Analg., September 1, 2005; 101(3): 926 - 926. [Full Text] [PDF]
|
|
|
|
|
|
F. J. Goldstein, S. Jeck, A. S. Nicholas, M. J. Berman, and M. Lerario Preoperative Intravenous Morphine Sulfate With Postoperative Osteopathic Manipulative Treatment Reduces Patient Analgesic Use After Total Abdominal Hysterectomy J Am Osteopath Assoc, June 1, 2005; 105(6): 273 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. White Changing Role of COX-2 Inhibitors in the Perioperative Period: Is Parecoxib Really the Answer? Anesth. Analg., May 1, 2005; 100(5): 1306 - 1308. [Full Text] [PDF]
|
|
|
